Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(8):597-606; doi:10.1093/jnci/94.8.597
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vallera, D. A.
Right arrow Articles by Hall, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vallera, D. A.
Right arrow Articles by Hall, W. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 8, 597-606, April 17, 2002
© 2002 Oxford University Press

ARTICLE

Targeting Urokinase-Type Plasminogen Activator Receptor on Human Glioblastoma Tumors With Diphtheria Toxin Fusion Protein DTAT

Daniel A. Vallera, Chunbin Li, Ni Jin, Angela Panoskaltsis-Mortari, Walter A. Hall

Affiliations of authors: D. A. Vallera, C. Li, N. Jin, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology–Radiation Oncology, University of Minnesota Cancer Center, Minneapolis; A. Panoskaltsis-Mortari (Department of Pediatrics) and W. A. Hall (Department of Neurosurgery), University of Minnesota.

Correspondence to: D. A. Vallera, Ph.D., University of Minnesota Cancer Center, Mayo Mail Code 367, Harvard St. at East River Rd., Minneapolis, MN 55455 (e-mail: valle001{at}tc.umn.edu).

Background: The prognosis for patients with brain cancer is poor, and new therapies are urgently needed. Recombinant toxic proteins that specifically target tumor cells appear to be promising. Urokinase-type plasminogen activator (uPA) receptor (uPAR) is expressed on the surface of glioblastoma and some other tumor cells and endothelial cells. We synthesized a recombinant fusion protein, DTAT, which contains the catalytic portion of diphtheria toxin (DT) for cell killing fused to the noninternalizing amino-terminal (AT) fragment of uPA, and investigated its effectiveness in targeting uPAR-positive tumor cells. Methods: In vitro cytotoxicity of DTAT was measured by cell proliferation assays. For in vivo studies, athymic nude mice (four to five animals/group) bearing uPAR-expressing human glioblastoma (U118MG) cell-induced tumors were injected with DTAT or control protein. Tumor volume was assessed over time, and differences between treatments were analyzed by Student's t test. Effects of DTAT on body organ systems were evaluated in normal, tumor-free C57BL/6 mice histologically and functionally by serum enzyme tests. All statistical tests were two-sided. Results: In vitro, DTAT was highly potent and selective in killing uPAR-expressing glioblastoma cells (U118MG, U373MG, and U87MG) and human umbilical vein endothelial cells. In vivo, compared with mice treated with control proteins, DTAT caused a statistically significant (P = .05) regression of small U118MG cell-induced tumors in all mice. Control fusion proteins that did not react with glioblastoma cells had no effect on tumor growth. DTAT given to tumor-free C57BL/6 mice had little effect on kidney, liver, heart, lung, and spleen histologies. Serum analysis in the same mice showed no elevation in blood urea nitrogen, indicating lack of effect on kidney function but a statistically significant (P = .046), albeit non-life-threatening, elevation in liver alanine aminotransferase levels. Conclusion: DTAT may have potential for intracranial glioblastoma therapy because of its ability to target tumor cells and tumor vasculature simultaneously and its apparent lack of systemic effects.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Gardsvoll, B. Gilquin, M. H. Le Du, A. Menez, T. J. D. Jorgensen, and M. Ploug
Characterization of the Functional Epitope on the Urokinase Receptor: COMPLETE ALANINE SCANNING MUTAGENESIS SUPPLEMENTED BY CHEMICAL CROSS-LINKING
J. Biol. Chem., July 14, 2006; 281(28): 19260 - 19272.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
D. A. Todhunter, W. A. Hall, E. Rustamzadeh, Y. Shu, S. O. Doumbia, and D. A. Vallera
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model
Protein Eng. Des. Sel., February 1, 2004; 17(2): 157 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. F. Liu, S. B. Tatter, M. C. Willingham, M. Yang, J. J. Hu, and A. E. Frankel
Growth Factor Receptor Expression Varies among High-Grade Gliomas and Normal Brain: Epidermal Growth Factor Receptor Has Excellent Properties for Interstitial Fusion Protein Therapy
Mol. Cancer Ther., August 1, 2003; 2(8): 783 - 787.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. F. Liu, K. A. Cohen, J. G. Ramage, M. C. Willingham, A. M. Thorburn, and A. E. Frankel
A Diphtheria Toxin-Epidermal Growth Factor Fusion Protein Is Cytotoxic to Human Glioblastoma Multiforme Cells
Cancer Res., April 15, 2003; 63(8): 1834 - 1837.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.